Everything below concerns responder analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
=== Books === Holick, MF (2011). The Vitamin D Solution: A 3-Step Strategy to Cure Our Most Common Health Problems. Plume 1st edition. ISBN 978-0452296886. Holick, MF; Dawson-Hughes, B (2010) [2004]. Nutrition and Bone Health. Humana Press. ISBN 978-1617374517. Holick, MF, ed. (2010). Vitamin D: Physiology, Molecular Biology, and Clinical Applications (2nd ed.). Humana Press. ISBN 978-1603273008. Holick, MF; Jenkins, Mark (2005). UV Advantage (2nd ed.). IBOOKS. ISBN 978-1596879003.
== Selected publications == Góngora-Benítez M, Tulla-Puche J, Albericio F (2014). Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chemical Reviews. doi:10.1021/Cr400031Z Subirós-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F (2010). Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.200900614 Ruiz-Sanchis P, Savina SA, Albericio F, Álvarez M. Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-b]indole. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.201001451 El-Faham A, Albericio F (2011). Peptide coupling reagents, more than a letter soup. Chemical Reviews. 111: 6557-602. doi:10.1021/Cr100048W Isidro-Llobet A, Alvarez M, Albericio F (2009). Amino acid-protecting groups. Chemical Reviews. doi:10.1021/Cr800323S Bruckdorfer T, Marder O, Albericio F (2004). From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Current Pharmaceutical Biotechnology. doi:10.2174/1389201043489620
In randomized controlled trials, meanwhile, these rates were 28%, 23.4% and 13.3%, respectively. In contrast to other selective serotonin reuptake inhibitors (SSRIs), initial trials showed that vilazodone did not cause decreased sexual desire/function, which often cause people to abandon their use. However, post-marketing experience led the FDA to warn that vilazodone may cause sexual dysfunction.
=== Middle East === Israel: BCG was given to all newborns between 1955 and 1982. Iran: Iran's vaccination policy was implemented in 1984. Vaccination with the Bacillus Calmette–Guerin (BCG) is among the most important tuberculosis control strategies in Iran [2]. According to Iranian neonatal vaccination policy, BCG has been given as a single dose to children aged <6 years, shortly after birth or at first contact with the health services.
== Licenses == As of 2025, a plurality (39%) of models released on Hugging Face used the permissive Apache 2.0 License. Some models, such as the source-available Llama 3, have licenses that grant some of the benefits of open-source licenses, but also contain legal restrictions that deter some companies from using those models, as the companies fear a future lawsuit or a change in the terms and conditions. Some of the same fears also exist in the large number of smaller models that do not specify a license.
Sources: en.wikipedia.org
==== Pale or gray ==== Stool that is pale or grey may be caused by insufficient bile output due to conditions such as cholecystitis, gallstones, giardia parasitic infection, hepatitis, chronic pancreatitis, or cirrhosis. Bile pigments from the liver give stool its brownish color. If there is decreased bile output, stool is much lighter in color.
Tasipimidine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α2-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs. It is also under development for the treatment of insomnia in humans. The drug is used as an oral solution in dogs, whereas its route of administration for humans is unspecified. The drug acts as a potent and selective full agonist of the human α2A-adrenergic receptor. Conversely, it is a much weaker agonist of the rodent α2B-, α2C-, and α2D-adrenergic receptors. In addition, it shows only low affinity for α1-adrenergic receptors, where it appears to act as a partial agonist. Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals. Tasipimidine is under development for use in humans by Orion Corporation. As of October 2024, it is in phase 2 clinical trials for this indication. The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported. It has reached phase 1 trials for psychiatric disorders. Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.
=== Logistics === Logistics vaccination services assure necessary equipment, staff, and supply of licensed vaccines across international borders. Central logistics include vaccine handling and monitoring, cold chain management, and safety of distribution within the vaccination network. The purpose of the COVAX facility is to centralize and equitably administer logistics resources among participating countries, merging manufacturing, transport, and overall supply chain infrastructure. Included are logistics tools for vaccine forecasting and needs estimation, in-country vaccine management, potential for wastage, and stock management. Other logistics factors conducted internationally during distribution of a COVID‑19 vaccine may include:
=== Positive effects === As the public becomes more aware of the stereotypical nature of mental illness depictions, there is an increasing number of studies being done to examine how media messages can positively affect audiences by decreasing stigma. Research has found that news stories are much more likely to produce positive audience comments and reactions if they use counter-stigmatism in their storytelling rather than stereotypes and discriminatory language. In a more specific sense, media portraying a realistic account of mental illness can give medical professionals a glimpse into the life and realities of living with such an illness. The research regarding the educational aspects of the film for nurse students from all fields suggested that the films of different genres, including life stories, adventures, and others, provided practical insights into understanding the patient experience and perspectives in different environments. Another research also found the positive aspects of the movies for educational purposes on students in medical (clinical) fields. The films provide valuable lessons for individuals in understanding the specific cases and appropriate treatment plans for patients. Even though there are some concerns that movies are not intended for educational purposes but for entertainment, researchers suggest that films provide positive outcomes in students' learning experiences.
In 2015, the school's name was changed to Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in response to a $30 million donation by the Jacobs family. The Jacobs family includes Jeremy Jacobs, the owner of the Boston Bruins. Before that, in 1987, the school's name was changed to the School of Medicine and Biomedical Sciences in recognition of the basic sciences underpinning medical knowledge. Today, the school enrolls 180 medical students each year, 133 PhD students, 28 MD/PhD students, 71 master's students and 435 undergraduates. Currently, the school is located at the Buffalo Niagara Medical Campus/University at Buffalo's downtown campus as of the Spring of 2018. In 2025, the school partnered with Rochester Institute of Technology (RIT) to offer a pre-admission program to the Jacobs school for eligible RIT students to gain medical training during their undergraduate at RIT.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.